The browser you are using is not supported by this website. All versions of Internet Explorer are no longer supported, either by us or Microsoft (read more here: https://www.microsoft.com/en-us/microsoft-365/windows/end-of-ie-support).

Please use a modern browser to fully experience our website, such as the newest versions of Edge, Chrome, Firefox or Safari etc.

Johan Korduner is a new WCMM doctor!

Johan Korduner, PhD graduate from Martin Magnusson's group

Johan Korduner, PhD graduate from Martin Magnusson’s group, defended his thesis “The heterogeneity of obesity for risk of cardiometabolic disease. Epidemiology and clinical aspects” on the 24th of March at the Department of Clinical Sciences in Malmö.

Johan was interested in exploring variants of obesity with lower risks of cardiometabolic disease and exploring the pathways between individuals with different mortality and morbidity risks. He used epidemiological data from the Malmö Diet and Cancer Study (MDCS) and sub-divided patients into different groups, depending on the absence or presence of hospitalization.

Firstly, Johan compared patterns and prognosis for cardiovascular disease and mortality of middle-aged people, who are obese but NOT hospitalized (healthy obese), to the same age-class people, who are obese AND hospitalized (unhealthy obese) and lastly to people who are NOT obese (not obese). During 20 years of follow-up in the MDCS, healthy obese individuals showed lower prospective risk of total mortality and cardiovascular morbidity than unhealthy obese. Interestingly, Johan did not observe differences between healthy obese and not obese people. Secondly, Johan further explored the metabolic profiles of healthy obese people and found that compared to unhealthy obese people, there is a downregulation of potentially harmful proteomic biomarkers. To go into details, Johan further elucidated in his third study the role of anti-phosphorylcholine (anti-PC, anti-inflammatory antibodies) in hospitalized and non-hospitalized subjects with obesity. His findings show that low levels of anti-PCs were associated with higher risk of being hospitalized.

Finally, Johan used a multiplex proteomic panel of 92 proteins associated with cardiovascular diseases, metabolism and inflammation and found that increased Galectin-4 levels were also associated with higher probability of being hospitalized. Although, the results were limited to subjects with diabetes, this still further implies the role of Galectin-4 in diabetes and the resulting effects of it.